Trends in Myocardial Infarction Secondary Prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012

被引:48
作者
Shah, Nilay S. [1 ,3 ]
Huffman, Mark D. [1 ,2 ]
Ning, Hongyan [1 ]
Lloyd-Jones, Donald M. [1 ,2 ]
机构
[1] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Med Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2015年 / 4卷 / 04期
关键词
myocardial infarction; secondary prevention; trends; CORONARY-HEART-DISEASE; ATHEROSCLEROTIC VASCULAR-DISEASE; HIGH BLOOD-PRESSURE; GLUCOSE CONTROL; UNITED-STATES; RISK-FACTORS; FOLLOW-UP; CHOLESTEROL; METAANALYSIS; PREVALENCE;
D O I
10.1161/JAHA.114.001709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Nationally representative data evaluating recent trends and future projections of vascular risk factor treatment and control rates in secondary prevention of ischemic heart disease are sparse. Methods and Results-We evaluated sex-and race-stratified cholesterol, blood pressure, and hemoglobin A1c levels and risk factor treatment and control rates in 1580 individuals who self-reported a history of myocardial infarction from The National Health and Nutrition Examination Surveys (NHANES) 1999 to 2012. We used weighted linear regression to estimate time trends and created forward linear projections to 2020. Participants were 30% to 41% women, 73% to 85% white, and had a mean age of 63 to 66 years. Cholesterol treatment rates increased and reached above 80% in men and women by 2011-2012, with significant increases in control rates (as then defined) in men to 85% in 2011-2012, with projections to reach 100% by 2020. Cholesterol treatment rates significantly increased in non-Hispanic whites and Hispanics. Statin use increased significantly to 73% of myocardial infarction survivors by 2011-2012, and aspirin use increased significantly but only to 28% by 2011-2012. There were no changes in blood pressure treatment or control rates by sex, and hypertension treatment increased only in non-Hispanic blacks. Projected hypertension control rates remained suboptimal. Conclusions-While temporal trends suggest improvements in cholesterol treatment, unchanged treatment and control of blood pressure and persistently low aspirin use represent missed opportunities. Urgent action is needed to improve secondary prevention rates projected by 2020 to reduce recurrent events in this high-risk group.
引用
收藏
页数:18
相关论文
共 44 条
  • [1] [Anonymous], 2014, HLTH PEOPL 2020
  • [2] [Anonymous], 2018, AN GUID 2011 2014 20
  • [3] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [4] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [5] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [6] Centers for Disease Control and Prevention, 2013, LEAD CAUS DEATH
  • [7] Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1065
  • [8] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1